FA TR
04 Dec 2021
Dr. Sattari, Vice President for Science and Technology, and Dr. Einollahi, Minister of Health and Medical Education, during their visit to the exhibition of "knowledge-based achievements in the field of health", got acquainted with the gamma probe device made by Parto Negar Persia Company.
02 Dec 2021
The new version of Gamma Probe surgical aid system with the exclusive name of GammaPen will be unveiled at the 9th laboratory equipment & chemicals exhibition.
01 Dec 2021
The second version of the Cardiac SPECT Imaging (ProSPECT II) will be unveiled at the 9th laboratory equipment & chemicals exhibition.
29 Nov 2021
The General SPECT System, the latest product of Parto Negar Persia Company, will be unveiled on 14 December, 2021 at the 9th laboratory equipment & chemicals exhibition (Iran Lab 2020).
14 Nov 2021
The products of Parto Negar Persia Company were exhibited in Tehran International Exhibition (Iran Innovation House I-Hit collection).
20 Jun 2021
Dr. Saeed Namaki, Minister of Health of Iran, and Dr. Sorena Sattari, Vice President for Science and Technology of the Republic of Iran visited the booth of Parto Negar Persia Company on June 16, 2021, during a visit to the permanent exhibition of the Iranian manufacturing technologies and got acquainted with the products of the company.
11 Feb 2021
Head of Yas Hospital, Dr. Jafari got acquainted with the Gamma probe system made by Parto Negar Persia Company during a visit to the iACT Skills Training Center located in the Advanced Medical Technologies and Equipment Institute on February 9, 2021.
27 Jan 2021
Iranian Vice-President for Science and Technology, Dr. Sorena Sattari, visited the booth of Parto Negar Persia Company on January 25, 2021, during a visit to the exhibition in the Iranian Land Complex and got acquainted with the products made by the PNP.
23 Jan 2021
According to the CEO of Parto Negar Persia Company, Dr. Mohammad Reza Ay, GammaPen system, a hand-held device with the capability of detection and localization of sentinel lymph nodes in breast cancer and for some masculine types of cancers, successfully passed the clinical tests and obtained the production license from the National Medical Device Directorate. An article on the device performance was also published in the international journal of Annals of Nuclear Medicine.